Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02393248
Title Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

endometrial cancer

lung squamous cell carcinoma

cholangiocarcinoma

myeloproliferative neoplasm

multiple myeloma

transitional cell carcinoma

breast cancer

Advanced Solid Tumor

stomach cancer

Therapies

Cisplatin + Gemcitabine + Pemigatinib

Docetaxel + Pemigatinib

Pemigatinib + Retifanlimab

Pemigatinib + Trastuzumab

Epacadostat + Pembrolizumab

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST